Literature DB >> 29947768

Association of Hypothyroidism With All-Cause Mortality: A Cohort Study in an Older Adult Population.

Huei-Kai Huang1, Jen-Hung Wang2, Sheng-Lun Kao1.   

Abstract

Context: Although hypothyroidism is associated with many comorbidities, the evidence for its association with all-cause mortality in older adults is limited. Objective: To evaluate the association between hypothyroidism and all-cause mortality in older adults. Design: Population-based retrospective cohort study. Setting: National Health Insurance Research Database in Taiwan. Patients: After 1:10 age/sex/index year matching, 2029 patients aged ≥65 years who received a new diagnosis of hypothyroidism between 2001 and 2011 and 20,290 patients without hypothyroidism or other thyroid diseases were included in the hypothyroidism and nonhypothyroidism cohorts, respectively. Main Outcome Measures: All-cause mortality was defined as the primary outcome. Cox proportional hazards regression models were used to calculate the hazard ratios of mortality. To further evaluate the effect of thyroxine replacement therapy (TRT) on mortality, we divided patients with hypothyroidism into two groups: patients who received TRT and those who did not.
Results: Hypothyroidism was associated with an increased risk of all-cause mortality [adjusted hazard ratio (aHR), 1.82; 95% CI, 1.68 to 1.98; P < 0.001]. Patients with hypothyroidism who received TRT had a lower risk of mortality than patients who did not receive TRT (aHR, 0.57; 95% CI, 0.49 to 0.66; P < 0.001). Similar results were obtained after further propensity score matching in age-, sex-, and comorbidity-stratified analyses. Conclusions: Hypothyroidism was independently associated with increased all-cause mortality in older adults. In patients with hypothyroidism, TRT was associated with a lower risk of all-cause mortality.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29947768     DOI: 10.1210/jc.2018-00408

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

2.  Predictability of Metabolic Syndrome Diagnosed by Body Mass Index for Cardiovascular Risk in Older Patients Treated with Levothyroxine.

Authors:  Fatma Özge Kayhan Koçak; Sumru Savas; Zeliha Fulden Saraç
Journal:  Ann Geriatr Med Res       Date:  2022-05-18

3.  Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study.

Authors:  Danbee Kang; Minwoong Kang; Yun Soo Hong; Jihwan Park; Jin Lee; Hwa Jeong Seo; Dong Wook Kim; Jin Seok Ahn; Yeon Hee Park; Se Kyung Lee; Dong Wook Shin; Eliseo Guallar; Juhee Cho
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.379

4.  Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment.

Authors:  Joanna Klubo-Gwiezdzinska; Leonard Wartofsky
Journal:  Pol Arch Intern Med       Date:  2022-03-03

5.  The association of thyroid stimulation hormone levels with incident ischemic heart disease, incident stroke, and all-cause mortality.

Authors:  Line Tang Møllehave; Tea Skaaby; Allan Linneberg; Nils Knudsen; Torben Jørgensen; Betina Heinsbæk Thuesen
Journal:  Endocrine       Date:  2020-02-10       Impact factor: 3.633

6.  Risk of All-Cause Mortality in Levothyroxine-Treated Hypothyroid Patients: A Nationwide Korean Cohort Study.

Authors:  Seo Young Sohn; Gi Hyeon Seo; Jae Hoon Chung
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-13       Impact factor: 5.555

7.  Fate of patients with slipped capital femoral epiphysis (SCFE) in later life: risk of obesity, hypothyroidism, and death in 2,564 patients with SCFE compared with 25,638 controls.

Authors:  Yasmin D Hailer
Journal:  Acta Orthop       Date:  2020-04-14       Impact factor: 3.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.